Japan · Delayed Price · Currency is JPY Japan Lifeline Earnings Call Transcripts
Fiscal Year 2027
-
Record Q1 net sales rose 8.8% year-over-year, but operating profit fell 9.4% due to higher R&D and personnel costs. Proprietary product launches and strong segment growth offset margin pressures, and the dividend forecast was raised to JPY 81 per share.
Fiscal Year 2026
-
Record sales and profits were achieved, driven by strong core and new product growth, despite margin pressure from inflation and one-time costs. FY 2027 guidance anticipates continued top-line growth but lower profits due to higher investments and relocation expenses.
-
9M sales set a record at JPY 44.40bn, up 3.7%, while operating and net profit declined amid margin pressure and one-time costs. Guidance was unchanged, with strong neurovascular and GI growth offset by PFA and CRM headwinds.
-
Record H1 sales and profits were driven by strong core and new segment growth, despite headwinds from PFA adoption and price revisions. International expansion and a regenerative medicine partnership marked key developments.
-
Q1 FY2026 delivered 4.3% revenue and 2.4% operating profit growth, with net profit down 1.6% due to FX losses and asset disposals. Strong gains in neurovascular and GI segments offset CRM and PFA-related declines. Progress aligns with full-year guidance.
Fiscal Year 2025
-
FY2025 delivered record sales and profits, with growth across core and newer businesses. FY2026 guidance targets further gains, while raised FY2028 goals reflect structural-heart entry and global expansion.
-
9M revenue, operating profit and net profit reached records, led by strong core and growth-segment sales. Full-year guidance and the dividend forecast were raised, while fewer Q4 business days and higher R&D spending are expected to temper results.